This study, conducted in ovarian epithelial (OVCAR-3, CaOV3) and folliculoma (COV434, KGN) cells, has demonstrated that SHLA and Lan-2 reversed the stimulatory effect of leptin on the HDACs in a cell-type-dependent manner and, therefore, they could show beneficial effects on the treatment of ovarian cancer. This evidence concerns the gene LEP and ovarian carcinoma.